However, the growth inhibition of TET2-knockdown DLBCL cells was observed after treatment with a histone deacetylase 3 (HDAC3) inhibitor in vitro.312 Clinically, AITL patients with TET2 mutations were reported to have an objective response to azacitidine treatment.313. This evidence concerns the gene HDAC3 and angioimmunoblastic T-cell lymphoma.